Abstract
Objective: The SOLO1 trial made it a priority to identify BRCA germline and somatic mutations in women with newly diagnosed epithelial ovarian cancer in order to determine candidates for olaparib maintenance. It is also important to differentiate between germline and somatic mutations because of the potential for cascade testing in relatives. Three testing strategies can be employed: (1) test all patients for germline mutations with reflex somatic testing if germline testing is negative; (2) test all tumors for somatic mutations with reflex germline testing if somatic testing is positive; or (3) perform simultaneous germline and somatic testing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
